Skip to main content

Medpace Holdings, Inc.

MEDP
Exchange
Nasdaq
Industry
Services-Commercial Physical & Biological Research
SEC CIK
0001668397

In the last 90 days, Medpace Holdings, Inc. insiders filed 0 open-market purchases and 16 sales; 754 institutions reported holding it in 13F filings for Q3 2026, worth $14.3B in total; superinvestors Giverny Capital and Fundsmith hold it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 23, 2026, 1:09 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Medpace Holdings, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedFeb 9, 2026Feb 10, 2025Feb 12, 2024Feb 13, 2023Feb 14, 2022
Revenue$2.53B$2.11B$1.89B$1.46B$1.14B
Selling, general and administrative$197.6M$180.2M$161.4M$131.4M$108.4M
Operating income$534.9M$446.9M$336.8M$278.7M$198.6M
Income tax$91.3M$71.5M$52.9M$37.5M$20.0M
Net income$451.1M$404.4M$282.8M$245.4M$181.8M
EPS, basic$15.64$13.06$9.20$7.57$5.06
EPS, diluted$15.28$12.63$8.88$7.28$4.81
Weighted shares, basic28.8M31.0M30.7M32.4M35.9M
Weighted shares, diluted29.5M32.0M31.8M33.7M37.7M
Margins and growth
Operating margin21.1%21.2%17.9%19.1%17.4%
Net margin17.8%19.2%15.0%16.8%15.9%
Revenue growth, year over year+20.0%+11.8%+29.2%+27.8%+23.4%
Net income growth, year over year+11.6%+43.0%+15.3%+34.9%+25.1%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Medpace Holdings, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedFeb 9, 2026Feb 10, 2025Feb 12, 2024Feb 13, 2023Feb 14, 2022
Cash and equivalents$497.0M$669.4M$245.4M$28.3M$461.3M
Accounts receivable$402.1M$296.4M$298.4M$253.4M$186.4M
Total current assets$989.6M$1.03B$593.8M$334.0M$690.9M
Property, plant and equipment$131.1M$123.6M$120.6M$109.8M$93.2M
Goodwill$662.4M$662.4M$662.4M$662.4M$662.4M
Intangible assets$33.4M$34.4M$35.8M$38.0M$41.4M
Total assets$1.98B$2.10B$1.66B$1.35B$1.66B
Accounts payable$28.1M$32.5M$31.9M$33.1M$25.7M
Short-term debt––$0$50.0M–
Total current liabilities$1.34B$1.10B$925.1M$803.5M$557.2M
Total liabilities$1.52B$1.28B$1.10B$966.1M$707.0M
Shareholders' equity$459.1M$825.5M$559.0M$386.4M$952.9M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Medpace Holdings, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedFeb 9, 2026Feb 10, 2025Feb 12, 2024Feb 13, 2023Feb 14, 2022
Operating cash flow$713.2M$608.8M$433.4M$388.1M$263.3M
Capital expenditures$31.4M$36.5M$36.6M$36.9M$28.3M
Free cash flow$681.9M$572.3M$396.7M$351.2M$235.1M
Stock-based compensation$34.8M$25.5M$20.5M$21.4M$14.5M
Share buybacks$917.4M$169.9M$144.0M$847.8M$62.1M
Investing cash flow-$31.1M-$28.3M-$34.6M-$38.7M-$31.4M
Financing cash flow-$860.4M-$154.0M-$182.6M-$775.8M-$44.5M
Net change in cash-$172.4M$424.0M$217.2M-$433.0M$183.5M
Ratio
Stock-based compensation, % of revenue1.4%1.2%1.1%1.5%1.3%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Medpace Holdings, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 16, 202628.0M−0.7%SEC
Jul 17, 202627.9M−0.6%SEC
Apr 17, 202628.6M−0.6%SEC
Feb 6, 202628.4M−6.8%SEC
Oct 17, 202528.2M−9.4%SEC
Jul 18, 202528.1M−9.4%SEC
Apr 18, 202528.7M−7.2%SEC
Feb 7, 202530.5M−1.0%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.